LEXINGTON, Mass., February 25, 2025--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced participation in a panel discussion at the B. Riley Securities Precision Oncology & Radiopharma Investor Conference that will take place on Friday, February 28th in New York.
Panel Discussion Details:
Speaker: Robin Taylor, Ph.D., Chief Commercial Officer
Topic: "What It Takes to Move the Needle in Improving Responses in Colorectal Cancer"’
Date: 02/28/2025
Time: 1:00-2:00 p.m. ET
Location: New York City, NY
This event is for in-person participants only. Contact B. Riley for information on attending the conference.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225022116/en/
Contacts
Investors
917-362-1370
investor@agenusbio.com
Media
510-323-5188
communications@agenusbio.com
Comments